• 2021 marked the year when Flora Growth held its IPO – the company’s common shares commenced trading on the Nasdaq Capital Market in May under the ticker symbol “FLGC”
• It also marked the year when the company ventured into the European market, as well as other key regions such as Mexico
• Significant acquisitions for the 2021 calendar year included Koch & Gsell, Vessel Brand Inc., and GMP-Certified Laboratory
• Flora Growth also made notable appointments to its executive leadership as well as its board of directors

Flora Growth (NASDAQ: FLGC) had an impressive year in 2021, highlighted by the company’s Initial Public Offering (“IPO”) in May, the addition of strategic team members and new products, and further expansion into global markets. Following the IPO, Flora Growth first ventured into the United Kingdom (“UK”) and Central American markets, marking the inaugural shipment of the company’s Mambe, Mind Naturals, and Almost Virgin Brands. Additionally, the company signed a distribution agreement with GMD Latinoamérica, a distributor based in Costa Rica that focuses on the Central American food and beverage market (https://ibn.fm/WCK5q). Flora Growth then expanded into the European Union (“EU”) after closing a €2 million investment in Hoshi International Inc., a fully integrated cannabis company (https://ibn.fm/SEapG). This led to the formation of a manufacturing division for cannabis products, Flora Lab, with a capacity to produce over 190 products. This division played an integral role in boosting Flora Growth’s 1,500+ distribution channels while also developing new cannabinoid and non-cannabinoid products to market. This move, furthermore, allowed for a 6% growth in the company’s share prices in May 2021 (https://ibn.fm/08hqc). The company also saw additions to its top-level management, with the appointment of Jason Warnock as the company’s Chief Revenue Officer (“CRO”) and Lee Leiderman as the Chief Financial Officer (“CFO”) (https://ibn.fm/4EHNx). Additionally, the company hired Dr. Annabelle Manalo-Morgan as its Lead Scientific Advisor and later as a member of its board of directors (https://ibn.fm/6RV95). Flora Growth marked some significant acquisitions for the 2021 financial year, with the main ones including Koch & Gsell, Vessel Brand Inc., and a GMP-Certified Laboratory. These acquisitions have been integral to its product diversification and to the overall expansion of its market reach. By the close of 2021, Flora Growth had added Mexico and Spain to the markets it operates in, marking an aggressive year-long market expansion campaign meant to create value for its shareholders. As it focuses on expanding globally and sustaining one of the largest outdoor cultivation facilities in the world, the company will benefit from the foundation laid down throughout the 2021 calendar year. With its strategic partnerships, acquisitions, and relationships with key players within specific global markets, Flora Growth is set to achieve increased sales and a growing market share for the 2022 calendar year, ultimately asserting its position as a leader in the global CBD sector. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform
• The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments
• According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements
• Both companies intend to pursue rigorous studies to achieve FDA clearance

Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping to transmute patient care and deliver improved clinical results, digital therapeutics (DTx) holds much promise. For one, it could potentially address unmet patient needs that conventional therapies and treatments have failed to resolve. With growing evidence indicating that DTx can decrease health care costs, personalize care, and bring about better outcomes (https://ibn.fm/3F3UB), Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is positioning itself to play a key role in this segment. Recently, the company signed a letter of intent (“LOI”) with Maya (https://ibn.fm/mI177). Under the terms of the LOI, both companies intend to collaborate to develop a novel DTx platform. Combined with Mindleap Health – Mydecine’s existing digital health platform that offers technology solutions such as telemedicine services and exclusive digital content to allow patients to improve their mental health, the DTx platform is expected to create a three-pronged approach to patient care. Once complete, for instance, physicians could prescribe the new digital therapeutic as a standalone option or in concert with Mydecine’s drug and therapy protocols. “The technology integration of the two software platforms is aimed at enhancing Mindleap’s medical capabilities to more quickly and efficiently develop a personalized prescription-based digital therapeutic that will not only complement Mydecine’s smoking cessation treatment [MYCO-001] but eventually for all primary and ancillary indications the company is targeting,” commented Damon Michaels, Mydecine Co-Founder, Director, and COO. “The new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements.” The new DTx platform, Mydecine says, aims to improve Mindleap by collecting and computing unique data to create more personalized treatments. The company believes it will enhance the efficacy of current treatment options by not only personalizing them to individual patients but also increasing their availability. “Maya’s clinically validated surveys, biometric tracking, and protocol customization combined with Mindleap’s telemedicine, exclusive digital content, and community features will allow both companies to accelerate the development and commercialization of a novel DTx platform,” said Mydecine in a recent news release. Maya and Mydecine intend to pursue rigorous studies to achieve FDA Section 510(k) clearance – integral to the platform’s registration – upon software integration and a comprehensive regulatory assessment. According to the company, the collaborative partnership will not affect or alter its existing programs, including the current smoking cessation clinical trial and Mindleap’s current consumer-facing offerings. A Deloitte article on DTx notes that companies that can take full advantage of emerging life sciences technology to address unmet patient needs, “in combination with faster product development timelines, could gain a significant advantage over traditional life sciences companies” (https://ibn.fm/TnnZ8). In this regard, Mydecine, which is leveraging the collaborative partnership with Maya to more quickly and efficiently develop a DTx platform, is ideally poised to gain a significant advantage in a market expected to grow at a 26.1% CAGR between 2021 and 2025, according to a report by The Business Research Company (https://ibn.fm/gsWLT). Maya is a platform that leverages real-world data and research to empower psychedelic practitioners with the ability to improve health outcomes and comprehensively map care journeys for safe psychedelic practices, reduced care cost, and increased IP equity. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Mullen Automotive launched the Mullen FIVE EV Crossover at the recent LA Auto Show, with the vehicle winning the auto show’s ZEVA(R) award for top all-electric SUV
• The Mullen FIVE has seen a spike in popularity following its debut, with the carmaker recently opting to lift the initial reservation limit to 25,000 vehicles
• The future Mullen FIVE’s RS is being modeled to usurp Tesla Model S Plaid’s title as the world’s fastest EV, with the ability to accelerate from 0-62 mph in a mere 1.9 seconds
• Mullen Automotive has recently entered a partnership with Germany’s ARRK to support the engineering development of the Mullen FIVE and future models within its pipeline
• Mullen Automotive is a Southern California-based EV company with an established manufacturing footprint outside Tunica, MS. Mullen recently started trading on the NASDAQ under ticker symbol MULN

“If this happens, the Tesla Model S Plaid will definitely have something to worry about.” (https://ibn.fm/94YOy) The quote, by Top Speed Magazine, refers to the development of the Mullen FIVE RS, a sportier version of emerging electric vehicle (“EV”) manufacturer Mullen Automotive’s (NASDAQ: MULN) flagship Mullen FIVE. The California-based automaker aims to set itself apart from the rest of the automotive pack through the creation of a sophisticated and luxurious crossover EV-SUV, a vehicle that has been meticulously designed by the creators of the famed Rolls Royce Ghost, all while boasting Tesla-rivaling performance (https://ibn.fm/n2jH9). The Mullen FIVE, starting at $55,000, is set to come equipped with a 95-kWh battery, allowing for a 325-mile (523 km) range, with the battery able to be charged up to 80 percent in just 21 minutes, thanks to its proprietary fast-charging capabilities. In terms of acceleration, the Mullen FIVE can do 0 to 62 mph (100 km/h) in 3.2 seconds, on its way to an electronically limited top speed of 155 mph (250 km/h). Those figures look even more impressive when seen through the lens of the future Mullen FIVE RS, which will have the ability to accelerate from 0 to 62 mph in a mere 1.9 seconds on its way to achieving a top speed of 200 mph. To put those figures into context, the Tesla Model S Plaid — currently the fastest EV in production — accelerates from 0 to 62 mph within 1.98 seconds. It comes as no surprise that the Mullen FIVE was the recipient of the recent Los Angeles Auto Show’s ZEVA Award for top all-electric SUV, beating out entries from the likes of Lincoln and Rivian (https://ibn.fm/TEH6a). Following the successful debut of its Mullen FIVE EV Crossover at the recent LA Auto Show, Mullen Technologies announced that the carmaker would be increasing the reservation limit for its flagship vehicle to 25,000 initial reservations, up from their original 5,000-unit target (https://ibn.fm/URPqR). “We’ve decided to increase the limit of the total number of FIVE reservations from 5,000 to 25,000 vehicles due to the strong demand in the first three days of the show,” said Jason Putnam, vice president of marketing for Mullen Automotive. “By establishing a 25,000-reservation limit, this allows us to offer a very special trim option package that will only be available to our initial ‘launch’ customer set.” Mullen Automotive plans to build the Mullen FIVE at its existing 127,000-square-foot Advanced Manufacturing and Engineering Center (“AMEC”) outside Tunica, Mississippi. It recently announced the addition of 1.2 million square feet for a body shop, paint shop and general assembly. The company also revealed that it had entered a strategic partnership with ARRK, a Munich, Germany-based automotive engineering company. The partnership will support the continued engineering development of the Mullen FIVE, with a focus on Computer Aided Engineering (CAE); body development with closures; high voltage battery housing; interior, chassis, and thermal management; and infotainment for the next 3-year period. The partnership will initially work towards the development of the Mullen FIVE EV Crossover, and then move on to the company’s future vehicle pipeline, which includes a seven-seat SUV program (https://ibn.fm/QODtY). Mullen also recently started public market trading on Nov. 5, 2021. You can find Mullen on the NASDAQ, under ticker symbol MULN (https://news.mullenusa.com/mullen-automotive-commences-trading-on-nasdaq). For more information about the Mullen FIVE, visit the company’s website at www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• SGMD’s Lemon Glow receives conditional use permit number from county
• Sugarmade’s seed-to-door vision separates the company from other players in the California cannabis marketplace
• Estimated for Lemon Glow property could reach as much as 64 tons of dry trimmed cannabis flower annually

Sugarmade (OTC: SGMD) is making significant progress toward its end goal of becoming a central play in the growing California cannabis space. The company announced that its wholly owned subsidiary, Lemon Glow Company, has received a conditional use permit (“UP”) number from the Community Development Department of the County of Lake, California (https://ibn.fm/zkjLq). The permit, noted Sugarmade, is an important step toward the conditional use permit for commercial cannabis cultivation at its property. “We are excited to see the process moving forward for our Lemon Glow property, which represents an important strategic asset as we further verticalize our overall model,” stated Sugarmade CEO Jimmy Chan. “Our vision is ‘seed to door,’ which would separate us from other players in the California cannabis marketplace, given that we have already established a leading and growing presence in the cannabis delivery market and have set in motion a process to control our own supply chain. Ramping up our cultivation resources is a significant step in fully leveraging a vertical model to drive shareholder value through margin gains.” Sugarmade has been focused on achieving its seed-to-door vision. Earlier this year, the company signed a definitive agreement outlining the acquisition of Lemon Glow Co., including all assets, interests, rights and property; the property acquisition included 640 acres in Lake County, outside of the Commercial Cannabis Cultivation Exclusion Zones (https://ibn.fm/SgkG3). The announced merger closed in May 2021. SGMD noted that the annual potential cultivation yield at the Lemon Glow property could reach as much as 4,000 pounds of dry trimmed cannabis flower per acre annually, or approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower annually. In order to reach those estimated, the necessary approvals and permits need to be obtained, including approval to designate 32 acres of the 640-acre Lemon Glow property as outdoor cannabis cultivation. With the conditional UP number in hand, Sugarmade is now turning its focus to the next steps necessary in order to achieve its strategic goals. “While [we believe] that the issuance of the conditional UP number by Lake County is an important step toward full approval to cultivate cannabis on the property, the company must still gain approval from other local and state regulatory authorities in California,” the company noted in the announcement. “Furthermore, the issuance of the conditional use permit number by the County of Lake allows the company to proceed with a state cannabis cultivation license application and applicable permits, such as those from the Department of Cannabis Control, the Department of Food and Agriculture, the Department of Pesticide Regulation, the Department of Fish and Wildlife, the State Water Resources Control Board, the Board of Forestry and Fire Protection, the Central Valley or North Coast Regional Water Quality Control Board, the Department of Public Health, and the Department of Consumer Affairs, as may be required.” Sugarmade has set its eyes on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while also developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade is working to develop a full farm-to-door vertically integrated cannabis business. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush(TM), NUG Avenue, Lemon Glow and Budcars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• The World Health Organization estimates by 2050 nearly 2.5 billion people will have some degree of hearing loss and at least 700 million will require hearing rehabilitation
• InnerScope Hearing Technologies has made transformational moves in 2021 to position itself as a leader in direct-to-consumer (“DTC”) sales of hearing aids and related products
• InnerScope recently acquired Hearing Assist II, Walmart’s largest hearing aid provider, and iHEAR Medical, the maker of the only FDA-cleared home hearing screener, setting up for what expects to be a record Q4 2021

As our homes have become our offices, schools, restaurants, and more throughout the coronavirus pandemic, they have also become our shopping centers, with direct-to-consumer (“DTC”) sales enjoying another banner year in 2021. Growing consumer familiarity coupled with new technologies is wending way for emerging markets, an opportunity that is squarely in the sights of InnerScope Hearing Technologies (OTC: INND), a DTC manufacturer and distributor of FDA-registered hearing aids, hearing assistive devices, hearing health-related products, and Personal Sound Amplifier Products (“PSAPs”). Hearing issues represent a substantial market in the U.S. and globally. Roughly 1 in 8 Americans over the age of 12 has hearing loss in both ears. At the macro level, the World Health Organization estimates that by 2050 nearly 2.5 billion people will have some degree of hearing loss and at least 700 million will require hearing rehabilitation. Data from the National Institute of Health’s National Institute on Deafness and Other Communication Disorders indicates that age is a discerning factor, including about 2% of the U.S. population aged 45-54, almost 25% of people 65-74 and 50%+ of Americans over the age of 75 having disabling hearing loss. Unfortunately, prohibitive costs have historically kept many of these people from using some type of applicable technology to help with their condition. Up until just recently, a prescription was required for hearing aids, which drove prices into the thousands of dollars, keeping them out of reach for many people. To that point, only about 16% of Americans aged 20-69 that could benefit from hearing aids have every used them, a figure that jumps to about 30 percent among people over age 70. InnerScope is aiming to break the persistent barriers with a full lineup of affordable hearing solutions designed to improve the quality of life of the 70 million people in North America who suffer from hearing impairment and/or hearing-related issues, including tinnitus. Tinnitus, an unexplained ringing in the ears, is an audiological and neurological condition experienced by nearly 50 million Americans. Using leading technology, InnerScope offers a variety of hearing health products that consumers can purchase online and save up to 70% compared to traditional brick and mortar clinics.  These hearing products includes Bluetooth app-controlled rechargeable hearing aids, hearing and tinnitus vitamins, assorted hearing aid ear cleaning products and much more. These hearing products can be purchased either as one-off sales or subscriptions through https://myheariq.com. 2021 was a transformational year for InnerScope, as it launched its hearing aid products along with deploying a one of a kind in-store Free Self-Check Hearing Screening Kiosks with some of the largest grocery and pharmacy retailers in the nation. InnerScope’s full line of hearing health products now being available through multiple retail/wholesale channels, including Amazon.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, and Walmart.com. Walmart is a significant growth driver for InnerScope going forward following the completion of the acquisition of Hearing Assist II, LLC in November. Hearing Assist is an established leader in the DTC hearing aid market with over 500,000 hearing aids sold and top-line revenues of more than $72 Million since 2018. The company is Walmart’s largest hearing aid supplier, with deployed product displays in 757 Walmart stores throughout five states. InnerScope said it expects record revenue during Q4 with the acquisition completed. The Hearing Assist acquisition came on the heels of InnerScope acquiring iHEAR Medical Inc. in October. Founded in 2010, iHEAR pioneered online DTC hearing solutions. The acquisition expanded InnerScope’s products and services to include the iHEARtest(TM), the only FDA-cleared home hearing screener, advanced FDA-registered hearing aids, and the TReO(TM) Personal Sound Amplification Product (“PSAP”). Furthermore, InnerScope onboarded the iHEAR customer base and established distribution network that included retailers/wholesalers CVS Pharmacy, AmerisourceBergen, Western States Pharmacy Coalition (“WSPC”), Good Neighbor Pharmacy, amongst others, and insurance partners VIA Benefits, , and Willis Towers Watson. InnerScope is hitting these milestones at time when the over-the-counter and DTC markets are ripe for disruption under calls by the Biden administration for affordable (and insurance-covered) hearing aids. Completing these acquisitions in combination with a shifting market landscape will have the investment community watching for how it translates to InnerScope’s top and bottom lines. For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• An estimated 91% of U.S. adults (91%) say either that marijuana should be legal for medical and recreational use or that it should be legal for medical use only
• While cannabis remains an illegal substance federally, a growing number of states have legalized the substance
• An emerging leader in the U.S. cannabis marketplace, NUGS’ vision is to acquire, scale assets in the legal cannabis market

A vast majority of adults in the United States say that marijuana should be legal for either medical and recreational use or at least for medical use, according to a recent Pew Research Center report (https://ibn.fm/zqnb9). Companies such as Cannabis Strategic Ventures (OTC: NUGS) look to those numbers in anticipation of a promising future. “As more states, including Virginia and New York, continue to legalize marijuana, an overwhelming share of U.S. adults (91%) say either that marijuana should be legal for medical and recreational use (60%) or that it should be legal for medical use only (31%),” the Power Research Center article notes. “Fewer than one in ten (8%) say marijuana should not be legal for use by adults.” While cannabis remains an illegal substance federally, a growing number of states have legalized the substance. “Lawmakers across the U.S. proved again in 2021 that marijuana reform will continue to advance on the state level despite the recalcitrance of Congress to end federal prohibition,” a “Marijuana Moment” article states (https://ibn.fm/fMloj). “As more eyes turn to 2022 legislative sessions, a report from NORML that was released on Monday details advocates’ progress on the cannabis front this year in more than 25 states, where over 50 pieces of marijuana reform legislation were enacted. Most notably, legislatures and governors in five states enacted recreational legalization — a notable trend given that the reform has historically been decided by voters as ballot initiatives,” the article continued. “But 2021 has also seen more modest policy changes related to medical cannabis, decriminalization and social equity. ‘State lawmakers took unprecedented steps this year to repeal marijuana prohibition laws and to provide relief to those millions of Americans who have suffered as a result of them,’ NORML Deputy Director Paul Armentano said.” As growing numbers of Americans of across a variety of ages and political affiliations support the legalization of cannabis, companies that are establishing a strong foothold in the industry stand to benefit. Cannabis Strategic Ventures is one of those companies. An emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator, the company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration. As part of that vision, Cannabis Strategic Ventures owns NUGS Farm North, a six-acre cannabis farm in Northern California. In addition, the company is committed to taking other steps to strengthen its position in the growing market, including working toward taking operational control of each license. The company also recently celebrated the opening of its cannabis dispensary and is looking to deploy another license to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. For more information, visit the company’s website at www.CannabisStrategic.com. NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://ibn.fm/NUGS

• The strategic move to incorporate SRAX is designed to bring investor visibility for all of the upcoming events that Lexaria has planned for 2022
• Lexaria’s patented DehydraTECH(TM) technology is poised to leverage multiple industries – notably the CBD industry, with a projected value of $108.8 billion by 2027
• The advertising and media contract will allow SRAX to engage and manage social media companies for the creation and distribution of advertising materials promoting Lexaria Bioscience

Lexaria Bioscience (NASDAQ: LEXX), an innovator of drug delivery platforms, announced that it will kick off 2022 with an advertising and media agreement with SRAX (NASDAQ: SRAX) for media buys and digital marketing. The announcement is the first in a long line of plans that the company has made for the new year, a year anticipated to be the busiest yet for the company. The strategic move to bring on SRAX will help Lexaria increase its visibility to the investor community, enhancing the company’s exposure across all networks (https://ibn.fm/nBGuM). Lexaria’s advertising and media contract with SRAX allows the latter to engage and manage media companies to create and distribute advertising materials made available online. SRAX will control when these communications are released to the online customer audience. As a financial technology company, SRAX uses cutting-edge algorithms to aid in maximizing engagement. Chris Bunka, CEO of Lexaria, commented on the advertising and media contract, saying that his company was pleased to be working with SRAX to inform and engage a broad investor community in a year-long media outreach campaign. “Lexaria has made tremendous progress during 2021, and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors,” Bunka added. The new year promises to be a busy one for the company, with several projects set to be initiated or conducted over the next 12 months:

• a six-week human clinical trial to study hypertension and evaluate Lexaria’s DehydraTECH-CBD for the potential hypertension relief
• a potentially industry-changing oral nicotine human study which will include both subjective evaluation and objective blood measurements to demonstrate the superiority of DehydraTECH-nicotine in comparison to leading industry products
• animal studies designed to evaluate DehydraTECH-CBD for seizure relief and a comparison against the only FDA-approved pharmaceutical in use for treatment against certain seizure disorders
• the company expects to complete its pre-IND meeting with the FDA during the new year and proceed with the IND application process, registering the clinical trial testing of DehydraTECH-CBD for hypertension

Lexaria’s patented DehydraTECH technology is designed to deliver fat-soluble drugs and other active pharmaceutical ingredients, increasing effectiveness and improving absorption into the bloodstream. By changing the way these pharmaceuticals are absorbed, Lexaria is speeding up the delivery and subsequent effects of the drug, increasing brain absorption, reducing drug administration costs, improving the potency of the drug, and even masking unwanted tastes. The company is positioned to leverage its technology to gain access and cement its position in several markets worth billions in forecasted market value. For example, in 2020, the cannabidiol (CBD) market size surpassed $7.1 billion and is estimated to grow at a CAGR of 35%, topping $108.8 billion by 2027. Listed drivers for growth include an increase in medical applications for CBD (much like Lexaria’s DehydraTECH technology), increased product adaptations, increased retail sales, and more (https://ibn.fm/Am3bk). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development
• CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”)
• CEO notes that CYB003 has the potential to achieve better patient outcomes

The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) early in 2022 (https://ibn.fm/MgASx). The meeting, which is scheduled to take place in Q1, takes the company a step closer to advancing its lead investigational candidate CYB003 into clinical development for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”). CYB003 is specifically formulated to address the shortcomings of existing treatments while retaining the therapeutic benefits of oral psilocybin, the company noted. “We believe that CYB003 has the potential to achieve better patient outcomes, including less variability, faster onset of action, shorter duration of effect, and improved brain penetration,” said Cybin CEO Doug Drysdale. “As a society, we need to prioritize the treatment of mental health, and Cybin is committed to taking these next important steps toward progressing psychedelics to therapeutics.” The meeting with the MHRA comes after the company announced preclinical data for CYB003 indicating that the compound demonstrated a 50% reduction in variability compared to oral psilocybin, which could mean more accurate dosing. The data also demonstrated a 50% reduction in dose compared to oral psilocybin, which potentially means that common side effects could be reduced. In addition, the data showed a 50% shorter time to onset and nearly double brain penetration, both indicators of potential benefits to developing CYB003 as an effective treatment for MDD and AUD. “Encouraged by positive preclinical findings that demonstrated the advantages of our novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health, we are moving rapidly to progress CYB003 toward clinical development,” said Drysdale. “We are looking forward to engaging with the MHRA to determine next steps for our clinical development path evaluating CYB003 for the treatment of MDD and AUD in the UK.” In addition to its upcoming meeting with MHRA, Cybin has announced plans to file a clinical trial application with the agency in 2022. A leading ethical biopharmaceutical company, Cybin is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Besides the monthly contest prizes, artists who promote three of their streams on Instagram and tag @fanpasslive have the opportunity to earn an additional $30 this month
• Fan Pass Live’s Winter Merchandise Collection is now available for purchase on the website – the merchandise is Fan Pass branded and features items like hoodies, socks, beanies, sweatpants, and more
• Fan Pass Live Artist Pro subscriptions are available for $8.99 per month and provide extra perks for artists on the platform

Mobile technology and marketing company Friendable Inc.’s (OTC: FDBL) Fan Pass Live platform has released its January contest for artists. The contest is titled “Win 2 Ways in January!” and is designed to reward artists who earn the most tips from their fans during streaming done throughout the month of January. In addition to the first-place prize of $500, the second-place prize of $250, and the third-place prize of $150, artists keep 100% of the tips they earn during their streams. As in previous months, the artists who promote at least three streams on Instagram and tag @fanpasslive win an additional $30. The Winter Collection of Fan Pass branded merchandise has also landed on the company’s online shop (https://ibn.fm/jwt6v). The Winter Collection will only be around for a limited time and features apparel such as hoodies, zip-up hoodies, denim t-shirt, zip-up piped fleece jackets, beanies, sweatpants, socks, and more. Some of these items are on sale for a limited time. Fan Pass Live’s merchandise section also makes it possible for fans to find merchandise from their favorite artists. One of the artists whose merchandise can be found in the Fan Pass Live shop is Brazy Luca (@itsbrazyluca), who took to Instagram to express appreciation for the platform. “This platform is really awesome, and communication from the staff is amazing! I love the fact that I am interacting with real people that really understand the true craft and realization of each artist,” Brazy Luca said in a post (https://ibn.fm/48NKI). Fan Pass Live’s staff has extensive music industry experience, starting from the top: co-founders (and brothers) Robert A. Rositano Jr. and Dean Rositano have spent over 25 years in the industry, working with various artists and helping them expand their revenue generating opportunities while giving fans what they want as well. One of Fan Pass Live’s most recent offerings designed to help artists earn more is Artist Pro, a subscription-based service that enables artists to give a more intimate experience to their fans. For only $8.99, Artist Pro includes:

• A VIP all-access subscription to view exclusive content on Fan Pass
• Activation of your individual merch store with a custom design
• Access to advanced analytics
• Your scheduled events promoted on Fan Pass platforms

Fan Pass Live’s artists who purchase any Pro Services can gain more control over their careers, from self-promotion to performances and revenue generation. Pro Services vary in price but offer services with three different tiers for logo, merchandise, and marketing designs. There is also a shop where artists can find all the equipment and accessories they need to put on the show of a lifetime. From acoustic foam panels to selfie-rings and DJ mixers to an entire recording bundle – Fan Pass Live’s shop hooks up artists with the best equipment to put on their livestreams. “We continue to build on each of our successes and learn more every single day from our artists, and that’s what it’s all about. Support is more than something you say, it’s really about what you do,” Robert A. Rositano Jr. said in a recent interview with the Los Angeles Tribune (https://ibn.fm/0Lqbi). “Our team prides itself on being the family all artists need, one in which the relationship goes both ways. It’s not about control; we should succeed together, which is what we are building here with Fan Pass Live.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Zacks Investment Research recently raised its forecast for SRAX’s 4Q21 revenues to $10.05mn, representing +122.3% YoY growth
• Zacks have also upped their fiscal year 2022 revenue forecast to $42.52 million, implying +35% YoY growth
• SRAX’s implied results look even more impressive given that it will no longer be consolidating the financials of key subsidiary, BIGtoken, following the latter company’s merger with BritePool, Inc
• SRAX’s future growth trajectory is set to be dictated by investor intelligence platform, Sequire, having recently recorded its twelfth consecutive quarter of revenue growth

SRAX (NASDAQ: SRAX) a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has seen its financial performance go from strength to strength over the past year. SRAX recently reported its third quarter results on November 15th, 2021, revealing third quarter revenues of $8.3 million, a figure which was up 219% year-over-year and 8% on a quarter-over-quarter basis. Zacks Investment Research, an American independent research and investment content advisory, has recently published its forecast for the upcoming quarter, projecting SRAX to report $10.05 million in sales for the current fiscal quarter. SRAX reported sales of $4.52 million over the same quarter last year, which would imply a theoretical year over year growth rate of 122.3%. SRAX is expected to publish its fourth quarter results on Monday, April 4th, 2022 (https://ibn.fm/HnE2o). According to the analysts at Zacks Investment Research, SRAX is expected to report full year sales of $31.48 million for the current fiscal year, with current analyst estimates ranging from $31.43 million to $31.53 million. Meanwhile and for 2022, Zacks expects SRAX to report sales of $42.52 million. SRAX’s large growth trajectory looks even more impressive in light of the news that the company will no longer consolidate the financials for its former subsidiary, BIGtoken, Inc following the latter company’s merger with BritePool, Inc; both companies formally announced the completion of their merger as of December 2, 2021, with the combined entity changing its corporate name to BIGtoken, Inc. Rather, SRAX will continue to hold a BIGtoken position on their balance sheet valued at nearly $4 million, with the carrying value of the equity set to be adjusted on a quarterly basis to mark the position to market. SRAX’s future growth will be driven by Sequire, SRAX’s investor intelligence platform, with Sequire having reported 3Q21 bookings of $8.9 million with Q4 set to rise to a record $12.5 million as of date. SRAX management revealed that they were projecting a further $4 million in Sequire bookings during the fourth quarter, a target which would drive the division’s total booked revenue in Q4 to $16.5 million and extend a run which has seen Sequire report twelve consecutive quarters of revenue growth. Christopher Miglino, Founder and CEO of SRAX elaborated on the results, “Our team continues to innovate on product, sales, and marketing; and this is translating into increased revenue. We will hit the high end of our 2021 guidance and are well positioned to close out 2021 strong, with an amazing 2022 on the horizon.” SRAX’s impressive results and growth trajectory have also played a significant role in bolstering its shareholder register, with several hedge funds and other institutional investors having recently added to their stakes in the business. BlackRock Inc. raised its stake in SRAX by 3.9% during the 3rd quarter, with the asset manager now possessing 70,504 shares of the business services provider’s stock worth $377,000 after acquiring an additional 2,653 shares during the period. Northern Trust Corp raised its stake in SRAX by 16.5% during the 2nd quarter, taking its stake up to 37,199 shares of the business services provider’s stock worth $202,000 after acquiring an additional 5,267 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in SRAX by 8.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 93,283 shares of the business services provider’s stock worth $507,000 after acquiring an additional 7,400 shares during the period. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX